Drain fluid iodine as a biomarker of anastomotic leak after low anterior resection in patients undergoing Gastrografin rectal tube flushes and omission of a diverting ileostomy: The GUSH study.

Aleksandra Edmundson, Brett McWhinney, David A Clark, Karen Dobeli, Darren Allen, Michael Lonne

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2025;27(2):e70031

PMID: 39973087

Abstract

AIM

Anastomotic leak (AL) is the anathema of colorectal surgery and its occurrence constitutes a serious risk to patients and places a substantial burden on the health system. The analysis of extravasated intraluminal substances in drain fluid has shown promise for the early detection of AL. The aim of this study is to assess the measurement of drain fluid iodine as a biomarker of AL.

METHOD

This prospective, observational, 2b exploration cohort study measured the iodine in drain fluid of patients undergoing a low colorectal anastomosis and without a diverting ileostomy (DI) when the rectal tube was flushed with Gastrografin®. Iodine was measured by dual-energy computed tomography (DECT) and inductively coupled plasma mass spectroscopy (ICPMS).

RESULTS

Sixty-six patients underwent a rectal resection and low colorectal anastomosis. Five patients experienced an AL. Four had grade C AL and returned to the operating theatre for peritoneal lavage and DI. The fifth was diagnosed at 30 days postoperatively and underwent image-guided drainage (grade B). The mean drain fluid iodine was significantly elevated in patients who experienced an AL compared with those who did not, as measured by DECT and ICPMS. The mean iodine value was 6.05 mg/mL vs. 0.088 mg/mL (p < 0.0001) for DECT and 41 437 μmol/L vs. 3.81 μmol/L (p < 0.0001) for ICPMS.

CONCLUSION

This study showed that drain iodine can be used as a sensitive indicator of early AL in patients undergoing a rectal resection with an extraperitoneal colorectal anastomosis and omission of a DI and when the rectal tube is flushed with Gastrografin following surgery.

© 2025 The Author(s). Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

Address: Department of General Surgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Mayne Academy of Surgery, University of Queensland, Brisbane, Australia.; Department of Surgery, St Vincent's Private Hospital Northside, Brisbane, Queensland, Australia.; Faculty of Medicine and Health, University of Sydney, and Surgical Outcomes Research Centre (SOuRCe), Sydney, New South Wales, Australia.; Department of Radiology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Department of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Department of General Surgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Department of Radiology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Department of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.